DEFA14A: Eli Lilly to Acquire Ventyx Biosciences for $1.2B

Eli Lilly and Company will acquire Ventyx Biosciences, Inc. for $1.2 billion in an all-cash transaction, offering shareholders a 62% premium.

Summary

• Eli Lilly and Company will acquire Ventyx Biosciences, Inc. for $14.00 per share in an all-cash transaction.
• The aggregate equity value of the transaction is approximately $1.2 billion.
• The purchase price represents a premium of approximately 62% to Ventyx's 30-day volume-weighted average price (VWAP) as of January 5, 2026.
• Ventyx's Board unanimously approved the transaction, determining it to be in the best interests of shareholders.
• The transaction is expected to close in the first half of 2026, subject to regulatory and stockholder approvals.
• Entities affiliated with New Science Ventures and all Ventyx directors and officers, representing approximately 10% of outstanding common stock, have signed voting and support agreements.

Sentiment

Score: 8

Explanation: The filing announces a definitive all-cash acquisition at a substantial premium, providing immediate and certain value to shareholders. The unanimous board approval and fairness opinions reinforce the positive sentiment, despite the inherent risks of merger completion.

Positives

• Shareholders receive significant and certain cash value.
• The transaction offers a compelling premium of approximately 62% over the 30-day VWAP as of January 5, 2026.
• Ventyx's programs will gain access to Eli Lilly's industry-leading resources, capabilities, and infrastructure, accelerating development.
• The Ventyx Board unanimously approved the deal, supported by fairness opinions from Jefferies LLC and Moelis & Company LLC.
• The transaction is not subject to any financing condition, reducing uncertainty.

Negatives

• No go-shop provision, limiting Ventyx's ability to solicit alternative acquisition proposals.
• A break-up fee is in place, which would be payable under certain circumstances if the deal does not close.
• Ventyx will cease to exist as a standalone public company, ending its independent pipeline development.

Risks

• The possibility that Ventyx's stockholders may not approve the adoption of the Merger Agreement.
• Ventyx's receipt of any competing offers or acquisition proposals.
• A failure to (or delay in) receiving the required regulatory clearances for the Merger.
• A condition to closing of the Merger may not be satisfied (or waived).
• The ability of each party to consummate the Merger.
• The closing of the Merger might be delayed or not occur at all.
• The diversion of management time and attention from ongoing business operations and opportunities.
• The response of competitors to the Merger.
• The effect of the Merger and the public announcement of the Merger on Ventyx's operations and its relationships with its suppliers, business partners, management and employees, including its ability to attract and retain key personnel.
• The successful integration of Ventyx and execution on the continued development of its programs following the closing of the Merger.
• The outcome of any legal proceedings that could be instituted against the parties to the Merger.
• The risks inherent in drug research, development and commercialization.
• Disruption in Ventyx's plans and operations attributable to the Merger.
• Changes in Ventyx's business during the period between announcement and closing of the Merger.
• The effects of the Merger (or the announcement thereof) on Ventyx's stock price.
• Relationships with key third parties or governmental entities.
• Regulatory changes and developments.
• The impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions.

Future Outlook

The transaction is expected to close in the first half of 2026, subject to customary closing conditions including regulatory and stockholder approvals. Following the merger, Ventyx's programs are anticipated to benefit from Eli Lilly's extensive resources, enabling larger and more long-term studies for their compounds.

Management Comments

• "This transaction follows a review by our Board to determine the most value-creating path for Ventyx."
• "Combining with Eli Lilly delivers a significant and certain cash value to our shareholders at a compelling premium and our Board unanimously determined this transaction was in their best interests."
• "We are excited to join a company that shares our mission and has the industry-leading resources, capabilities and infrastructure to help us accelerate our work."
• "Our Board is focused on pursuing the most value-creating path for Ventyx."
• "By partnering with Lilly, Ventyx's programs will be met with the resources necessary to perform larger, more long-term studies on our compounds – the next step in their development."
• "We anticipate a smooth process in securing shareholder approval for the merger."

Industry Context

This acquisition reflects a continuing trend in the pharmaceutical and biotechnology sectors where larger, established companies acquire smaller biotechs with promising pipelines to bolster their R&D capabilities and product portfolios. For Ventyx, joining Eli Lilly provides the substantial capital and infrastructure often necessary to advance drug candidates through costly and lengthy clinical development stages, a common challenge for standalone biotechs.

Comparison to Industry Standards

• The 62% premium over the 30-day VWAP is a strong indicator of value for Ventyx shareholders, often exceeding typical premiums seen in biotech acquisitions, which can range from 30-50%.
• The all-cash nature of the deal provides immediate and certain value, contrasting with stock-based deals that expose sellers to market volatility of the acquirer's shares.
• The absence of a go-shop provision is common in highly negotiated deals where the target board believes it has achieved the best available offer, but it can sometimes be viewed as limiting potential for higher bids compared to deals like the recent acquisition of Seagen by Pfizer, which included a limited go-shop period.
• The unanimous board approval and fairness opinions from two reputable financial advisors (Jefferies LLC and Moelis & Company LLC) align with best practices for ensuring fiduciary duties are met in M&A transactions.

Stakeholder Impact

• Shareholders: Will receive $14.00 per share in cash, representing a significant premium and certain value.
• Employees: Ventyx's programs will continue under Eli Lilly, potentially offering new opportunities and resources, but also potential integration challenges and changes in roles.
• Patients: Ventyx's drug development programs are expected to accelerate with Eli Lilly's resources, potentially bringing new therapies to patients faster.
• Suppliers/Business Partners: Relationships may be affected by the change in ownership and integration into Eli Lilly's operations.

Next Steps

• Ventyx will file a proxy statement with the SEC for the solicitation of proxies to approve the merger agreement.
• Ventyx will mail the definitive proxy statement and a WHITE proxy card to stockholders.
• Stockholders will vote to approve the transaction.
• The transaction is subject to customary closing conditions, including regulatory approvals.
• The transaction is expected to close in the first half of 2026.

Key Dates

Recommendation

The filing announces a definitive all-cash acquisition of Ventyx Biosciences by Eli Lilly at $14.00 per share, representing a substantial 62% premium over the 30-day VWAP. This offers immediate, certain, and significant value to Ventyx shareholders. Given the unanimous board approval, fairness opinions, and voting agreements from key stakeholders, the likelihood of the deal closing is high. For current shareholders, holding until closing is advisable to realize the premium. For investors not currently holding, a "strong buy" recommendation is appropriate to capture the arbitrage spread between the current market price and the acquisition price, assuming the current price is below $14.00 and the deal is highly likely to close.

Keywords

Ventyx Biosciences, Eli Lilly, Acquisition, Merger, Biotechnology, Pharmaceuticals, Drug Development, VTX3232, SEC Filing, Proxy Statement, Shareholder Value, Premium